Continuous quality improvement (CQI) in rhu-Epo management: the outcome.
The establishment of an adequate recombinant erythropoietin (epo) treatment for haemodialysis patients has challenged nephrology workers for the last 5 years. Starting with epo, it was quickly clear that its management was complex and a lot of conditions were involved in its effective application.
Descamps
C
C
Nephrology Unit, University Hospital, Antwerp.
Van Waeleghem
J P
JP
Ysebaert
D
D
D000465:Algorithms; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D003663:Decision Trees; D016903:Drug Monitoring / Q000379:methods; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D010347:Patient Care Planning; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000592:standards*; D017749:Total Quality Management / Q000379:methods*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004921:Erythropoietin